Japan-based Astellas Pharma Inc. (ALPMY) said Wednesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for the development of ASP5354, based on non-clinical and clinical data.
from RTT - Biotech https://ift.tt/3mn8MXw
via IFTTT
No comments:
Post a Comment